Literature DB >> 20465296

Concise formal synthesis of (-)-salinosporamide A (marizomib) using a regio- and stereoselective epoxidation and reductive oxirane ring-opening strategy.

Taotao Ling1, Barbara C Potts, Venkat R Macherla.   

Abstract

Expedient access to a highly functionalized 2-pyrrolidinone (8), the gamma-lactam core of 20S proteasome inhibitor (-)-salinosporamide A (marizomib; NPI-0052; 1), using a regio- and stereoselective epoxide formation/reductive oxirane ring-opening strategy is presented. Notably, the sequential construction of the C-4, C-3, and C-2 stereocenters of 1 in a completely stereocontrolled fashion is a key feature of streamlining the synthesis of intermediate 12. A related strategy is also discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20465296     DOI: 10.1021/jo100432g

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  6 in total

Review 1.  Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.

Authors:  Tobias A M Gulder; Bradley S Moore
Journal:  Angew Chem Int Ed Engl       Date:  2010-12-03       Impact factor: 15.336

2.  Bioinspired total synthesis and human proteasome inhibitory activity of (-)-salinosporamide A, (-)-homosalinosporamide A, and derivatives obtained via organonucleophile promoted bis-cyclizations.

Authors:  Henry Nguyen; Gil Ma; Tatiana Gladysheva; Trisha Fremgen; Daniel Romo
Journal:  J Org Chem       Date:  2010-11-03       Impact factor: 4.354

3.  Total Synthesis of (-)-Salinosporamide A via a Late Stage C-H Insertion.

Authors:  Hadi Gholami; Aman Kulshrestha; Olivia K Favor; Richard J Staples; Babak Borhan
Journal:  Angew Chem Int Ed Engl       Date:  2019-04-10       Impact factor: 15.336

Review 4.  Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

Authors:  B C Potts; M X Albitar; K C Anderson; S Baritaki; C Berkers; B Bonavida; J Chandra; D Chauhan; J C Cusack; W Fenical; I M Ghobrial; M Groll; P R Jensen; K S Lam; G K Lloyd; W McBride; D J McConkey; C P Miller; S T C Neuteboom; Y Oki; H Ovaa; F Pajonk; P G Richardson; A M Roccaro; C M Sloss; M A Spear; E Valashi; A Younes; M A Palladino
Journal:  Curr Cancer Drug Targets       Date:  2011-03       Impact factor: 3.428

Review 5.  Acyclic Twisted Amides.

Authors:  Guangrong Meng; Jin Zhang; Michal Szostak
Journal:  Chem Rev       Date:  2021-08-18       Impact factor: 72.087

6.  Tetramate Derivatives by Chemoselective Dieckmann Ring Closure of threo-Phenylserines and Their Antibacterial Activity.

Authors:  Liban Saney; Kirsten E Christensen; Xiang Li; Miroslav Genov; Alexander Pretsch; Dagmar Pretsch; Mark G Moloney
Journal:  J Org Chem       Date:  2022-09-02       Impact factor: 4.198

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.